Rights offering: round 1 issue price set

What happened

NGeneBio / Rights offering: round 1 issue price set / (2026.07.20) Rights offering: round 1 issue price set

Rights offering: round 1 issue price set 1. Planned issuance details a. Type of shares: registered common shares b. Number of shares (shares): 7,150,000 2. Round 1 issue price (per share): 1,074 won 3. Par value (KRW): 1,000 4. Round 1 issue price calculation date: 2026-07-16 5. Other matters for reference in investment decisions This notice discloses the round 1 issue price; the final issue price will be calculated on September 4, 2026 under the formula below and disclosed on September 7, 2026. Under Article 5-18 of the Regulation on Issuance and Disclosure, etc. of Securities, with the abolition of the pricing procedure for shareholder-allotment capital increases and the liberalization of pricing, the issue price may be freely determined; however, due to concerns about market disruption and existing practice, the price is determined as follows by applying, in part, the former Article 57 of the Regulation on Issuance and Disclosure, etc. of Listed Securities. (1) Round 1 issue price: using the 3rd trading day before the new-share allotment record date as the base date, the round 1 reference price is the lower of (i) the arithmetic mean of the 1-month volume-weighted arithmetic mean price, the 1-week volume-weighted arithmetic mean price, and the base-date volume-weighted arithmetic mean price established on the KOSDAQ market, and (ii) the base-date volume-weighted arithmetic mean price; the round 1 issue price is then determined under the formula below with a 25% discount rate applied. (Amounts below the quotation unit are rounded up to the quotation unit, and if the resulting price is below par value (KRW 1,000), par value applies.) Round 1 issue price = reference price x (1 - discount rate) / [1 + (capital increase ratio x discount rate)] (2) Round 2 issue price: using the 3rd trading day before the existing-shareholder subscription date as the base date, the round 2 reference price is the lower of (i) the arithmetic mean of the 1-week volume-weighted arithmetic mean price and the base-date volume-weighted arithmetic mean price established on the KOSDAQ market, and (ii) the base-date volume-weighted arithmetic mean price, discounted by 25%. (Amounts below the quotation unit are rounded up to the quotation unit, and if the resulting price is below par value (KRW 1,000), par value applies.) Round 2 issue price = reference price x (1 - discount rate) (3) Final issue price: the lower of the round 1 issue price and the round 2 issue price. However, pursuant to Article 165-6 of the Financial Investment Services and Capital Markets Act and Article 5-15-2 of the Regulation on Issuance and Disclosure, etc. of Securities, if the lower of the round 1 and round 2 issue prices is lower than the price obtained by applying a 40% discount to the volume-weighted arithmetic mean price for the 3rd to 5th trading days before the existing-shareholder subscription date, that latter price shall be the final issue price. (Amounts below the quotation unit are rounded up to the quotation unit, and if the resulting price is below par value (KRW 1,000), par value applies.) Final issue price = Max[Min(round 1 issue price, round 2 issue price), 60% of the volume-weighted arithmetic mean price for the 3rd to 5th trading days before the subscription date] The final issue price will be determined on the 3rd trading day before the first day of the existing-shareholder subscription period and disclosed on the Financial Supervisory Service's electronic disclosure system (DART), and will be announced on the Company's website (http://www.ngenebio.com) in lieu of individual notice. Related disclosure date: 2026-04-27